抗人 F8 抗体对
01AB03351
Coagulation factor VIII (FVIII) is a crucial protein in the blood clotting process. It is produced primarily in the liver and circulates in the bloodstream bound to von Willebrand factor. When activated, FVIII acts as a cofactor for factor IX, catalyzing the activation of factor X and ultimately leading to fibrin clot formation. Mutations in the F8 gene, which encodes FVIII, can result in hemophilia A, the most common form of this bleeding disorder. Over 1,300 different mutations have been identified, ranging from single base pair changes to large inversions. These mutations can lead to reduced FVIII production or abnormal protein function, impairing the blood clotting process and causing excessive bleeding. Conversely, elevated FVIII levels have been associated with increased risk of venous thromboembolism and may be an independent risk factor for arterial thrombotic diseases such as myocardial infarction and stroke.
| 规格 | 起售价 |
|---|---|
| 登录后可查看 | |
技术参数
- 靶点基因名
- F8
- 基因别名
- F8C
- 蛋白别名
- coagulation factor VIII; F8
- UniProt
- P00451
- 物种
- Human
产品详情
- 靶点名称
- F8
- 蛋白名称
- coagulation factor VIII
- 蛋白别名
- Coagulation factor VIII; Antihemophilic factor; AHF; Procoagulant component) [Cleaved into: Factor VIIIa heavy chain; 200 kDa isoform; Factor VIIIa heavy chain; 92 kDa isoform; Factor VIII B chain; Factor VIIIa light chain]
- 靶点基因名
- F8
- 基因别名
- F8C
- UniProt
- P00451
- 来源物种
- Homo sapiens (Human)
- 物种反应性
- Human
背景介绍
Coagulation factor VIII (FVIII) is a crucial protein in the blood clotting process. It is produced primarily in the liver and circulates in the bloodstream bound to von Willebrand factor. When activated, FVIII acts as a cofactor for factor IX, catalyzing the activation of factor X and ultimately leading to fibrin clot formation. Mutations in the F8 gene, which encodes FVIII, can result in hemophilia A, the most common form of this bleeding disorder. Over 1,300 different mutations have been identified, ranging from single base pair changes to large inversions. These mutations can lead to reduced FVIII production or abnormal protein function, impairing the blood clotting process and causing excessive bleeding. Conversely, elevated FVIII levels have been associated with increased risk of venous thromboembolism and may be an independent risk factor for arterial thrombotic diseases such as myocardial infarction and stroke.